Dermapharm Holding SE: binding offer to acquire Arkopharma Group
Dermapharm Holding SE / Key word(s): Takeover
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
Grünwald, July 30, 2022 – Today, Dermapharm AG, wholly owned subsidiary of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8), offered to acquire 100% of the shares in Apharma TopCo SAS, headquartered in Carros, France, from private equity firm Montagu and minority shareholders of the target, for a purchase price approximating EUR 450 million.
Apharma TopCo SAS is the holding company of the Arkopharma Group, a provider of herbal OTC products and dietary supplements in France and other European countries. In the financial year 2021, Arkopharma Group achieved sales of approximately EUR 191 million. For the current financial year 2022, it forecasts sales of slightly over EUR 200 million.
The execution of the corresponding share purchase agreement is subject to the consultation of the works council of certain French companies of the Arkopharma Group. The Management Board expects the transaction to be completed at the beginning of January 2023.
>End of the Ad hoc announcement <
Investor Relations & Corporate Communications
30-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Dermapharm Holding SE|
|Phone:||+49 (0)89 64 86-0|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange|
|EQS News ID:||1409691|
|End of Announcement||DGAP News Service|